# Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy

> **NCT01787994** · PHASE1 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 10 (actual)

## Conditions studied

- HIV

## Interventions

- **GENETIC:** Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.

## Key facts

- **NCT ID:** NCT01787994
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01787994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01787994, "Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01787994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*